Literature DB >> 29491079

Dose-function Histogram Evaluation Using 99mTc-GSA SPECT/CT Images for Stereotactic Body Radiation Therapy Planning for Hepatocellular Carcinoma Patients: A Dosimetric Parameter Comparison.

Ryo Toya1, Tetsuo Saito2, Shinya Shiraishi3, Yudai Kai4, Ryuji Murakami5, Tomohiko Matsuyama2, Takahiro Watakabe2, Fumi Sakamoto3, Noriko Tsuda3, Yoshinobu Shimohigashi4, Yasuyuki Yamashita3, Natsuo Oya2.   

Abstract

BACKGROUND/AIM: We evaluated the influence of previous treatments on the parametric discrepancies between dose-volume histograms (DVHs) and dose-function histograms (DFHs) generated based on 99mTc-GSA SPECT images of hepatocellular carcinoma (HCC) patients treated with stereotactic body radiation therapy (SBRT). PATIENTS AND METHODS: Twelve patients underwent SBRT at 30-40 Gy. Registration between planning CT and SPECT/CT images was performed, and DFH parameters were calculated as follows: Fx=(sum of the counts within the liver volume receiving a dose of more than x Gy/sum of the counts within the whole liver volume) ×100. The discrepancy between Fx and Vx (Dx) was also calculated.
RESULTS: The number of previous treatments for lesions other than SBRT-treated lesions (≥2 vs. <2) exhibited a significant influence on the absolute values of D10, D15, and D20 (p<0.05).
CONCLUSION: Previous treatment significantly influences the parametric discrepancy between DFH and DVH. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Hepatocellular carcinoma; dose–function histogram; dose–volume histogram; radiation-induced liver disease; stereotactic body radiation therapy

Mesh:

Substances:

Year:  2018        PMID: 29491079     DOI: 10.21873/anticanres.12378

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Implementation of 99mTc-GSA SPECT Image-guided Inverse Planning into Palliative Radiotherapy for Diffuse Liver Metastases: A Novel Approach.

Authors:  Ryo Toya; Takahiro Watakabe; Yudai Kai; Tomohiko Matsuyama; Yoshiyuki Fukugawa; Tadashi Matsumoto; Shinya Shiraishi; Yoshinobu Shimohigashi; Sho Saeki; Takuro Sakagami; Toshinori Hirai; Natsuo Oya
Journal:  In Vivo       Date:  2022 May-Jun       Impact factor: 2.406

2.  Functional Liver Imaging in Radiotherapy for Liver Cancer: A Systematic Review and Meta-Analysis.

Authors:  Pi-Xiao Zhou; Ying Zhang; Quan-Bin Zhang; Guo-Qian Zhang; Hui Yu; Shu-Xu Zhang
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

3.  Stereotactic Body Radiotherapy Based on 99mTc-GSA SPECT Image-guided Inverse Planning for Hepatocellular Carcinoma.

Authors:  Yudai Kai; Ryo Toya; Tetsuo Saito; Tomohiko Matsuyama; Yoshiyuki Fukugawa; Shinya Shiraishi; Yoshinobu Shimohigashi; Natsuo Oya
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

4.  Impact of 99mTc-GSA SPECT Image-Guided Inverse Planning on Dose-Function Histogram Parameters for Stereotactic Body Radiation Therapy Planning for Patients With Hepatocellular Carcinoma: A Dosimetric Comparison Study.

Authors:  Ryo Toya; Tetsuo Saito; Yudai Kai; Shinya Shiraishi; Tomohiko Matsuyama; Takahiro Watakabe; Fumi Sakamoto; Noriko Tsuda; Yoshinobu Shimohigashi; Yasuyuki Yamashita; Natsuo Oya
Journal:  Dose Response       Date:  2019-03-04       Impact factor: 2.658

5.  99m-Technetium galactosyl human serum albumin scanning to evaluate liver function after stereotactic body radiotherapy for hepatocellular carcinoma: A case report.

Authors:  Osamu Tanaka; Kazutaka Miki; Takuya Taniguchi; Takao Kojima; Akihiro Ohbora; Chiyoko Makita; Masayuki Matsuo
Journal:  Radiol Case Rep       Date:  2019-09-23

6.  Impact of four-dimensional cone-beam computed tomography on target localization for gastric mucosa-associated lymphoid tissue lymphoma radiotherapy: reducing planning target volume.

Authors:  Yoshinobu Shimohigashi; Ryo Toya; Tetsuo Saito; Yumiko Kono; Yasuhiro Doi; Yoshiyuki Fukugawa; Takahiro Watakabe; Tadashi Matsumoto; Yudai Kai; Masato Maruyama; Natsuo Oya
Journal:  Radiat Oncol       Date:  2021-01-14       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.